Compounds > 5'-noraristeromycin
Page last updated: 2024-11-07

5'-noraristeromycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5'-noraristeromycin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126704
CHEMBL ID129014
SCHEMBL ID1231088
MeSH IDM0206481

Synonyms (23)

Synonym
(1s,2r,3s,4r)-4-(6-aminopurin-9-yl)cyclopentane-1,2,3-triol
(+/-)-(1-.alpha.-,2-.beta.-,3-.beta.-,4-.alpha).-4-(6-amino-9h-purin-9-yl)-1,2,3-cyclopentanetriol
(+/-)-5'-noraristeromycin
(-)-(1s,2r,3s,4r)-4-(6-amino-purin-9-yl)-cyclopentane-1,2,3-triol
(-)-5'-noraristeromycin
5'-noraristeromycin
(1s,2r,3s,4r)-4-(6-amino-9h-purin-9-yl)cyclopentane-1,2,3-triol
bdbm50135288
(1s,2r,3s,4r)-4-(6-amino-purin-9-yl)-cyclopentane-1,2,3-triol
CHEMBL129014 ,
noraristeromycin
(+-)-(1alpha,2beta,3beta,4alpha)-4-(6-amino-9h-purin-9-yl)-1,2,3-cyclopentanetriol
1,2,3-cyclopentanetriol, 4-(6-amino-9h-purin-9-yl)-, (1alpha,2beta,3beta,4alpha)- (+-)-
4-(6-amino-9h-purin-9-yl)cyclopentane-1,2,3-triol
142635-42-5
SCHEMBL1231088
NRN ,
150132-22-2
DTXSID40931561
Q27463913
CS-0613777
HY-148151
(-)-5 inverted exclamation marka-noraristeromycin

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Since most efforts have focused on the development of nucleoside analog inhibitors, issues regarding bioavailability and selectivity have been major challenges."( A new structural class of S-adenosylhomocysteine hydrolase inhibitors.
Chun, TG; Kim, BG; Lee, HY; Snapper, ML, 2009)		0.35

Dosage Studied

ExcerptRelevanceReference
" Moreover, twice daily oral therapeutic dosage of 1 mg/kg of NAM significantly inhibited the paw swelling and disease progression even after the occurrence of experimental CIA."( A novel IKKα inhibitor, noraristeromycin, blocks the chronic inflammation associated with collagen-induced arthritis in mice.
Asamitsu, K; Hamano, T; Ito, M; Komatsu, T; Okamoto, T; Yamakawa, T, 2014)		0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AdenosylhomocysteinaseHomo sapiens (human)IC50 (µMol)1.76670.00152.11118.7000AID199466; AID318694; AID328970
AdenosylhomocysteinaseHomo sapiens (human)Ki0.16000.00000.18991.9300AID199472
AdenosylhomocysteinasePlasmodium falciparum 3D7IC50 (µMol)2.43331.10002.43333.1000AID199440; AID318695; AID477477
AdenosylhomocysteinasePlasmodium falciparum 3D7Ki0.18000.18000.18000.1800AID199441
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
one-carbon metabolic processAdenosylhomocysteinaseHomo sapiens (human)
S-adenosylmethionine cycleAdenosylhomocysteinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
adenosylhomocysteinase activityAdenosylhomocysteinaseHomo sapiens (human)
protein bindingAdenosylhomocysteinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusAdenosylhomocysteinaseHomo sapiens (human)
endoplasmic reticulumAdenosylhomocysteinaseHomo sapiens (human)
cytosolAdenosylhomocysteinaseHomo sapiens (human)
melanosomeAdenosylhomocysteinaseHomo sapiens (human)
extracellular exosomeAdenosylhomocysteinaseHomo sapiens (human)
cytosolAdenosylhomocysteinaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (98)

Assay IDTitleYearJournalArticle
AID46787Tested for concentration required to cause a microscopically detectable alteration of CEM cell morphology1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID86503Activity against coxsackie B4 virus induced cytopathicity in HeLa cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID81196Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- VZV virus in HEL cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID33205Binding affinity determined by displacement of specific binding of [125I]N-(4-amino-3-iodophenethyl)-adenosine in membranes of CHO cells stably transfected with the rat Adenosine A3 receptor1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID63782The minimum inhibitory concentration required to reduce HSV-2(G) virus induced cytopathicity by 50% was measured on E6SM cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID83344The minimum inhibitory concentration required to reduce CMV(Davis) virus induced cytopathicity by 50% was measured on HEL cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID208054Inhibitory concentration on human T-lymphocyte Molt4 (clone 8) cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID31885Binding affinity to adenosine A1 receptor in rat brain membranes by measuring displacement of specific [3H]PIA as radioligand.1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID99824Inhibitory concentration on L929 cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID328970Inhibition of human recombinant SAHH2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis of 4'-modified noraristeromycins to clarify the effect of the 4'-hydroxyl groups for inhibitory activity against S-adenosyl-L-homocysteine hydrolase.
AID83343The minimum inhibitory concentration required to reduce CMV(AD-169) virus induced cytopathicity by 50% was measured on HEL cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID87159Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against respiratory syncytial virus in HeLa cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID63912The minimum inhibitory concentration required to reduce Vesicular Stomatitis Virus induced cytopathicity by 50% in E6SM cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID63770Activity against HSV-2(G) virus induced cytopathicity in E6SM cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID63772Activity against VV virus induced cytopathicity in E6SM cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID217904Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against semliki forest virus in Vero cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID217899Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in Vero cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID83336Activity against VZV (OKA) induced cytopathicity in HEL cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID71877Inhibitory activity against mammalian FM3A cell2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID46793The minimum inhibitory concentration required to reduce HIV-2(ROD) virus induced cytopathicity by 50% was measured on CEM cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID86516The minimum inhibitory concentration required to reduce Polio-1 virus induced cytopathicity by 50% in HeLa cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID477477Inhibition of Plasmodium falciparum S-adenosyl-homocysteine hydrolase2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
A new structural class of S-adenosylhomocysteine hydrolase inhibitors.
AID83334Activity against CMV (AD-169) induced cytopathicity in HEL cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID216511The minimum inhibitory concentration required to reduce Arenavirus (Tacaribe) induced cytopathicity by 50% was measured on Vero cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID66941Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- HSV-1 virus in E6SM cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID63911The minimum inhibitory concentration required to reduce Vaccinia virus induced cytopathicity by 50% in E6SM cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID86517The minimum inhibitory concentration required to reduce RSV(Long) virus induced cytopathicity by 50% in HeLa cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID86504Activity against parainfluenza-3 virus induced cytopathicity in HeLa cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID216360Activity against sindbis virus induced cytopathicity in Vero cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID63769Activity against HSV-1(KOS) virus induced cytopathicity in E6SM cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID87158Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against polio 1 virus in HeLa cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID216357Activity against junin virus induced cytopathicity in Vero cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID105962Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against influenza B virus in MDCK cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID66943Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in E6SM cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID208052Inhibitory concentration on human T-lymphocyte CEM/0 cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID105802Tested for the concentration required to cause a microscopically detectable alteration of MCDK cell morphology1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID157671Inhibitory activity against Plasmodium falciparum2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID199472Inhibitory activity against human S-adenosyl-L-homocysteine hydrolase2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID105804The minimum inhibitory concentration required to reduce Influenza B virus induced cytopathicity by 50% was measured on MDCK cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID66942Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vaccinia virus in E6SM cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID83335Activity against CMV (Davis) induced cytopathicity in HEL cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID216512The minimum inhibitory concentration required to reduce Parainfluenza virus type 3(ATCC VR-93) induced cytopathicity by 50% in Vero cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID66939Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-1 virus in E6SM cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID199582Mean value of human S-adenosyl-L-homocysteine hydrolase to that of Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID328968Inhibition of Plasmodium falciparum recombinant SAHH2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis of 4'-modified noraristeromycins to clarify the effect of the 4'-hydroxyl groups for inhibitory activity against S-adenosyl-L-homocysteine hydrolase.
AID235642Selectivity index was evaluated [Selectivity = (CC50 / EC50) against Hepatitis B virus in human hepatoblastoma cell line]1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives?
AID216510The minimum inhibitory concentration required to reduce Arenavirus (Junin) induced cytopathicity by 50% was measured on Vero cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID63779Tested for concentration required to cause a microscopically detectable alteration of E6SM cell morphology1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID83348The minimum inhibitory concentration required to reduce VZV(YS) virus induced cytopathicity by 50% was measured on HEL cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID86501Activity against RSV (strain Long) virus induced cytopathicity in HeLa cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID63781The minimum inhibitory concentration required to reduce HSV-1(KOS) virus induced cytopathicity by 50% was measured on E6SM cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID86872Effective concentration against Hepatitis B virus in human hepatoblastoma cell line1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives?
AID218231Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against parainfluenza 3 virus in Vero cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID232912Mean value of mammalian FM3A cell to that of Plasmodium falciparum.2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID318694Inhibition of human SAHH2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID199440Inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID86505Activity against polio-1 virus induced cytopathicity in HeLa cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID86873Effective concentration against Hepatitis B virus in human hepatoblastoma cell line1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives?
AID216358Activity against reovirus-1 induced cytopathicity in Vero cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID86510Tested for concentration required to cause a microscopically detectable alteration of HeLa cell morphology1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID199466Inhibitory activity against human S-adenosyl-L-homocysteine hydrolase2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID218378Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against sindbis virus in Vero cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID105784Activity against influenza A virus induced cytopathicity in MDCK cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID86518The minimum inhibitory concentration required to reduce Vesicular Stomatitis Virus induced cytopathicity by 50% in HeLa cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID216359Activity against semliki forest virus induced cytopathicity in Vero cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID83337Activity against VZV (YS) induced cytopathicity in HEL cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID86502Activity against VSV virus induced cytopathicity in HeLa cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID83347The minimum inhibitory concentration required to reduce VZV(Oka) virus induced cytopathicity by 50% was measured on HEL cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID218232Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against tacaribe virus in Vero cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID86515The minimum inhibitory concentration required to reduce Coxsackie B4 virus induced cytopathicity by 50% in HeLa cells.1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID80126Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HCMV virus in HEL cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID87160Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in HeLa cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID328972Selectivity ratio of human recombinant SAHH to Plasmodium falciparum recombinant SAHH2008Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8
Synthesis of 4'-modified noraristeromycins to clarify the effect of the 4'-hydroxyl groups for inhibitory activity against S-adenosyl-L-homocysteine hydrolase.
AID105961Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against influenza A virus in MDCK cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID33792Binding affinity to adenosine A2A receptor in rat striatal membranes by measuring displacement of specific [3H]-CGS- 21680 as radioligand1995Journal of medicinal chemistry, Mar-31, Volume: 38, Issue:7
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.
AID217900Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against junin virus in Vero cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID66940Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-2 virus in E6SM cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID63771Activity against VSV virus induced cytopathicity in E6SM cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID83342Tested for the concentration required to cause a microscopically detectable alteration of HEL cell morphology1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID216361Activity against tacaribe virus induced cytopathicity in Vero cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID318695Inhibition of Plasmodium falciparum SAHH2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID46792The minimum inhibitory concentration required to reduce HIV-1(IIIB) virus induced cytopathicity by 50% was measured on CEM cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID46779Activity against HIV-1 induced cytopathicity in CEM cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID105803The minimum inhibitory concentration required to reduce Influenza A virus induced cytopathicity by 50% was measured on MDCK cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID87157Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in HeLa cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID217901Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against measles virus in Vero cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID217903Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against reo type 1 virus in Vero cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID105786Activity against influenza B virus induced cytopathicity in MDCK cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID46780Activity against HIV-2 induced cytopathicity in CEM cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID216500Tested for concentration required to cause a microscopically detectable alteration of Vero cell morphology1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID216515The minimum inhibitory concentration required to reduce Sindbis virus (ATCC VR-67) induced cytopathicity by 50% in Vero cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID199441Inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase2003Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22
Synthesis of 2-fluoronoraristeromycin and its inhibitory activity against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID216513The minimum inhibitory concentration required to reduce Reo-1 virus (ATCC VR-230) induced cytopathicity by 50% was measured in Vero cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID318698Selectivity ratio of IC50 for human SAHH to IC50 for Plasmodium falciparum SAHH2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase.
AID98928Inhibitory concentration on murine leukemia L1210/0 cells1994Journal of medicinal chemistry, Feb-18, Volume: 37, Issue:4
Antiviral enantiomeric preference for 5'-noraristeromycin.
AID216514The minimum inhibitory concentration required to reduce forest virus (ATCC VR-67) induced cytopathicity by 50% in Vero cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
3-deaza- and 7-deaza-5'-noraristeromycin and their antiviral properties.
AID81197Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against VZV virus in HEL cells1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID86871Cytotoxic concentration against Hepatitis B virus in human hepatoblastoma cell line1998Journal of medicinal chemistry, Jun-04, Volume: 41, Issue:12
Does the anti-hepatitis B virus activity of (+)-5'-noraristeromycin exist in its 4'-epimer and 4'-deoxygenated derivatives?
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (32.00)18.2507
2000's13 (52.00)29.6817
2010's4 (16.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.14 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		2.08106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
9-xylosyladenine
9-xylosyladenine: RN given refers to cpd with unspecified isomeric designation; structure in first source		1.9810purine nucleoside
3-deazaadenosine
[no description available]		1.9810
foscarnet
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.		1.9910carboxylic acid;
one-carbon compound;
phosphonic acids		antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor
tubercidin
Tubercidin: An antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids.. tubercidin : An N-glycosylpyrrolopyrimidine that is adenosine in which the in the 5-membered ring that is not attached to the ribose moiety is replaced by a carbon. Tubercidin is produced in the culture broth of Streptomyces tubericidus.		1.9810antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside		antimetabolite;
antineoplastic agent;
bacterial metabolite
ornithine
Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.		2.0310non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
2-chloroadenosine
5-chloroformycin A: structure given in first source		1.9810purine nucleoside
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		2.0310cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
2'-deoxyadenosine
2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source		1.9810purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
cladribine
[no description available]		1.9810organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
hyaluronoglucosaminidase
kinetin riboside: preferentially induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells; structure in first source		1.9810purine nucleoside
vidarabine
adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.		1.9810beta-D-arabinoside;
purine nucleoside		antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic
3-deazaadenosine
3-deazaadenosine: RN given refers to parent cpd.		1.9810
ribavirin
Rebetron: Rebetron is tradename		2.39201-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
lamivudine
[no description available]		1.9910monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		4.37200adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
aristeromycin
aristeromycin: RN given refers to (1R-(1alpha,2alpha,3beta,5alpha)-isomer		2.6930
sinefungin
[no description available]		2.0310adenosines;
non-proteinogenic alpha-amino acid		antifungal agent;
antimicrobial agent
metrifudil
[no description available]		1.9810
illimaquinone
illimaquinone: structure given in first source; isolated from the Red Sea sponge Smenospongia; inhibits the RNase H. activity of HIV-1 reverse transcriptase		2.0510monohydroxy-1,4-benzoquinones;
prenylquinone		metabolite
neplanocin a
neplanocin A: neplanocins are antitumor antibiotics & carbocyclic analogs of purine nucleosides from Ampullarilla regularis A11079; see also neplanocin B, neplanocin C, neplanocin D & neplanocin F; structure in first source; a potent inhibitor of S-adenosylhomocysteine hydrolase		2.9140
3-deazaneplanocin
3-deazaneplanocin: S-adenosylhomocysteine hydrolase antagonist		1.9910
9-(2',3'-dihydroxycyclopentan-1'-yl)adenine
9-(2',3'-dihydroxycyclopentan-1'-yl)adenine: inhibitor of S-adenosylhomocysteine hydrolase; structure given in first source		2.4220
n(6)-benzyladenosine
N(6)-benzyladenosine: RN given refers to parent cpd		1.9810
8-bromoadenosine
[no description available]		1.9810purine nucleoside
8-aminoadenosine
[no description available]		1.9810
2'-o-methyladenosine
cordysinin B : A member of the class of adenosines that is adenosine in which the hydroxy group at position 2' is replaced by a methoxy group. It has been isolated from the mycelia of Cordyceps sinensis.		1.9810adenosines;
ether		fungal metabolite
5-ethynyl-1-ribofuranosylimidazole-4-carboxamide
5-ethynyl-1-ribofuranosylimidazole-4-carboxamide: used in therapy of experimental leukemia		1.9910
5'-deoxy-5'-s-isobutylthioadenosine
5'-deoxy-5'-S-isobutylthioadenosine: considered an analog of S-adenosylhomocysteine; structure		210
n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine: structure given in first source; a selective A(3) adenosine receptor agonist. 3-iodobenzyl-5'-N-methylcarboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by N-ethylcarboxamido and one of the hydrogens of the exocyclic amino function is substituted by a 3-iodobenzyl group.		1.9810adenosines;
monocarboxylic acid amide;
organoiodine compound		adenosine A3 receptor agonist
eritadenine
eritadenine: isolated from Lentinula edodes (Shiitake mushroom); inhibits S-adenosyl-L-homocysteine hydrolase activity		2.0510
2-hexynyladenosine-5'-n-ethylcarboxamide
2-hexynyladenosine-5'-N-ethylcarboxamide: adenosine receptor agonist		1.9810
3-deazaadenine
[no description available]		2.0810
5'-methylthioadenosine
5'-methylthioadenosine: structure. 5'-S-methyl-5'-thioadenosine : Adenosine with the hydroxy group at C-5' substituted with a methylthio (methylsulfanyl) group.		2.110thioadenosinealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
5'-deoxyadenosine
5'-deoxyadenosine: main heading DEOXYADENOSINE refers to the 3' cpd. 5'-deoxyadenosine : A 5'-deoxyribonucleoside compound having adenosine as the nucleobase.		1.98105'-deoxyribonucleoside;
adenosines		Escherichia coli metabolite;
human metabolite;
mouse metabolite
brivudine
brivudine: anti-herpes agent		1.9810
adenosine-5'-(n-ethylcarboxamide)
Adenosine-5'-(N-ethylcarboxamide): A stable adenosine A1 and A2 receptor agonist. Experimentally, it inhibits cAMP and cGMP phosphodiesterase activity.. N-ethyl-5'-carboxamidoadenosine : A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.		1.9810adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
3'-c-methyladenosine
3'-C-methyladenosine: structure in first source		1.9810
fludarabine
[no description available]		1.9810purine nucleoside
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		2.0810aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
1-aminoadenosine
1-aminoadenosine: structure		1.9810
ribose
ribopyranose : The pyranose form of ribose.		1.9910D-ribose;
ribopyranose
pyrazofurin
pirazofurin : A C-glycosyl compound that is 4-hydroxy-1H-pyrazole-5-carboxamide in which the hydrogen at position 3 has been replaced by a beta-D-ribofuranosyl group.		1.9910C-glycosyl compound;
pyrazoles		antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Cytomegalovirus
A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.		02.730
Leukemia L 1210
[description not available]		02.3920
Infections, Plasmodium
[description not available]		02.0810
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.0810
Disease Exacerbation
[description not available]		02.110
Adjuvant Arthritis
[description not available]		02.110
Innate Inflammatory Response
[description not available]		02.110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.110
Viral Diseases
[description not available]		02.0810
Virus Diseases
A general term for diseases caused by viruses.		02.0810